Cullinan Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $319K | Hold |
8,675
| – | – | 0.03% | 180 |
|
|
2025
Q4 | $441K | Hold |
8,675
| – | – | 0.03% | 163 |
|
|
2025
Q3 | $481K | Hold |
8,675
| – | – | 0.03% | 170 |
|
|
2025
Q2 | $599K | Hold |
8,675
| – | – | 0.04% | 158 |
|
|
2025
Q1 | $602K | Hold |
8,675
| – | – | 0.04% | 153 |
|
|
2024
Q4 | $746K | Sell |
8,675
-325
| -4% | -$35.1K | 0.05% | 148 |
|
|
2024
Q3 | $1.06M | Sell |
9,000
-400
| -4% | -$53.3K | 0.06% | 135 |
|
|
2024
Q2 | $1.34M | Sell |
9,400
-4,000
| -30% | -$530K | 0.08% | 128 |
|
|
2024
Q1 | $1.72M | Hold |
13,400
| – | – | 0.1% | 123 |
|
|
2023
Q4 | $1.39M | Hold |
13,400
| – | – | 0.08% | 133 |
|
|
2023
Q3 | $1.22M | Hold |
13,400
| – | – | 0.07% | 137 |
|
|
2023
Q2 | $1.08M | Hold |
13,400
| – | – | 0.06% | 151 |
|
|
2023
Q1 | $1.07M | Sell |
13,400
-2,116
| -14% | -$150K | 0.06% | 153 |
|
|
2022
Q4 | $1.05M | Buy |
15,516
+2,116
| +16% | +$124K | 0.06% | 155 |
|
|
2022
Q3 | $668K | Hold |
13,400
| – | – | 0.04% | 162 |
|
|
2022
Q2 | $747K | Hold |
13,400
| – | – | 0.05% | 153 |
|
|
2022
Q1 | $744K | Hold |
13,400
| – | – | 0.04% | 160 |
|
|
2021
Q4 | $750K | Hold |
13,400
| – | – | 0.04% | 158 |
|
|
2021
Q3 | $643K | Hold |
13,400
| – | – | 0.04% | 167 |
|
|
2021
Q2 | $561K | Hold |
13,400
| – | – | 0.03% | 168 |
|
|
2021
Q1 | $452K | Hold |
13,400
| – | – | 0.03% | 163 |
|
|
2020
Q4 | $468K | Buy |
13,400
+5,000
| +60% | +$173K | 0.03% | 151 |
|
|
2020
Q3 | $292K | Hold |
8,400
| – | – | 0.02% | 160 |
|
|
2020
Q2 | $275K | Hold |
8,400
| – | – | 0.02% | 163 |
|
|
2020
Q1 | $253K | Hold |
8,400
| – | – | 0.02% | 156 |
|
|
2019
Q4 | $243K | Hold |
8,400
| – | – | 0.02% | 170 |
|
|
2019
Q3 | $217K | Hold |
8,400
| – | – | 0.02% | 171 |
|
|
2019
Q2 | $214K | Hold |
8,400
| – | – | 0.02% | 176 |
|
|
2019
Q1 | $220K | Sell |
8,400
-600
| -7% | -$14.7K | 0.02% | 174 |
|
|
2018
Q4 | $207K | Hold |
9,000
| – | – | 0.02% | 178 |
|
|
2018
Q3 | $212K | Hold |
9,000
| – | – | 0.02% | 175 |
|
|
2018
Q2 | $208K | Hold |
9,000
| – | – | 0.02% | 176 |
|
|
2018
Q1 | $222K | Hold |
9,000
| – | – | 0.02% | 176 |
|
|
2017
Q4 | $242K | Hold |
9,000
| – | – | 0.02% | 174 |
|
|
2017
Q3 | $217K | Buy |
+9,000
| New | +$203K | 0.02% | 183 |
|
|
2016
Q3 | – | Sell |
-9,000
| Closed | -$242K | – | 204 |
|
|
2016
Q2 | $242K | Hold |
9,000
| – | – | 0.02% | 189 |
|
|
2016
Q1 | $244K | Buy |
+9,000
| New | +$241K | 0.02% | 185 |
|
Other funds holding NVO
DAM
F
Cullinan Associates's NVO Position: Q1 2026 in Review
Cullinan Associates held its Novo Nordisk (NVO) position steady in Q1 2026 at 8,675 shares worth $319K. The position accounts for 0.03% of the portfolio, ranked #180.
Cullinan Associates first reported a position in NVO in Q1 2016 and has held it in 37 quarters since. The position peaked at $1.72M in Q1 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Cullinan Associates held 8,675 shares of Novo Nordisk worth $319K as of Q1 2026.
- Cullinan Associates left its Novo Nordisk share count unchanged in Q1 2026.
- Novo Nordisk made up 0.03% of Cullinan Associates's portfolio in Q1 2026, its #180 holding.
- Cullinan Associates first reported a position in Novo Nordisk in Q1 2016 and has held it in 37 quarters since.
- Cullinan Associates's Novo Nordisk position peaked at $1.72M in Q1 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Cullinan Associates's 13F filing for Q1 2026, filed 1 May 2026.